Enterprise Therapeutics

OverviewSuggest Edit

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.
In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

TypePrivate
Founded2014
HQFalmer, GB
Websiteenterprisetherapeutics.com

Latest Updates

Employees (est.) (Sept 2021)13(-7%)
Cybersecurity ratingAMore

Key People/Management at Enterprise Therapeutics

John Ford

John Ford

Chief Executive Officer, Board Member
Amit Munshi

Amit Munshi

Chairman
Martin Gosling

Martin Gosling

Chief Scientific Officer
Paul Russell

Paul Russell

Head of Development
Peter Finan

Peter Finan

Board Member
David Morris

David Morris

Chief Medical Officer
Show more

Enterprise Therapeutics Office Locations

Enterprise Therapeutics has an office in Falmer
Falmer, GB (HQ)
Science Park Square
Show all (1)

Enterprise Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2014

Enterprise Therapeutics total Funding

$59.6 m

Enterprise Therapeutics latest funding size

$7.26 m

Time since last funding

2 years ago

Enterprise Therapeutics investors

Enterprise Therapeutics's latest funding round in October 2019 was reported to be $7.3 m. In total, Enterprise Therapeutics has raised $59.6 m
Show all financial metrics

Enterprise Therapeutics Revenue

Cash (31-Mar-2018)

172.6k
GBPFY, 2016FY, 2017FY, 2018

Cash

446.9k30.8k172.6k

Accounts Receivable

273.0

Current Assets

461.0k42.9k178.3k
FY, 2016

Financial Leverage

1.2 x
Show all financial metrics

Enterprise Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Enterprise Therapeutics Online and Social Media Presence

Embed Graph

Enterprise Therapeutics Blogs

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

ETD001 is a novel inhaled, long-acting ENaC inhibitor Therapy applicable to all cystic fibrosis patients, independent of genotype Brighton, UK, 14 June 2021: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve…

Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by Roche

Enterprise’s novel TMEM16A potentiator portfolio includes ETD002, a first in class compound which is currently in Phase 1 TMEM16A potentiation is a novel therapeutic approach applicable to all cystic fibrosis patients, independent of CFTR genotype, and may provide benefit in other respiratory diseas…

Enterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002

ETD002 is a novel TMEM16A chloride channel potentiator Therapy applicable to all cystic fibrosis patients, independent of genotype Brighton, UK, 17 August 2020: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to impr…

Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer

Dr Morris will lead Enterprise’s therapeutics development strategy and drive the Company’s two lead respiratory programmes through the clinic Brighton, UK, 10 February 2020: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel ther…

Enterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patients

“TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis” published in American Journal of Respiratory and Critical Care Medicine Paper demonstrates first in class TMEM16A chloride channel potentiators, to accelerate mucociliary clearance Co-authored by researchers fr…

TMEM16A Channel Function Does Not Influence Goblet Cell Numbers or Mucin Secretion In The Human Airway Epithelium – NACFC – Nashville – October 2019

TMEM16A Channel Function Does Not Influence Goblet Cell Numbers or Mucin Secretion In The Human Airway Epithelium – NACFC – Nashville – October 2019 Henry Danahay1,2, Alexis Flen, Camille Ehre3, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK; 3University of North…
Show more

Enterprise Therapeutics Frequently Asked Questions

  • When was Enterprise Therapeutics founded?

    Enterprise Therapeutics was founded in 2014.

  • Who are Enterprise Therapeutics key executives?

    Enterprise Therapeutics's key executives are John Ford, Amit Munshi and Martin Gosling.

  • How many employees does Enterprise Therapeutics have?

    Enterprise Therapeutics has 13 employees.

  • Who are Enterprise Therapeutics competitors?

    Competitors of Enterprise Therapeutics include YiChang HEC ChangJiang Pharmaceutical, Mankind Pharma and Chiesi Group.

  • Where is Enterprise Therapeutics headquarters?

    Enterprise Therapeutics headquarters is located at Science Park Square, Falmer.

  • Where are Enterprise Therapeutics offices?

    Enterprise Therapeutics has an office in Falmer.

  • How many offices does Enterprise Therapeutics have?

    Enterprise Therapeutics has 1 office.